Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

53,121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapy.
Khadadah FM, Cerquozzi S, Olney HJ, Fraga C, Dudebout J, Xenocostas A, Finn N, Ethier V, Savoie ML, Busque L, Jamani K, Kuruvilla P, Faught C, Leber B, Kaedbey R, Assouline SE, Kim D. Khadadah FM, et al. Among authors: kim d. Leuk Res. 2023 Oct;133:107374. doi: 10.1016/j.leukres.2023.107374. Epub 2023 Aug 22. Leuk Res. 2023. PMID: 37657146
Optimal duration of imatinib treatment/deep molecular response for treatment-free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial.
Kim DDH, Novitzky-Basso I, Kim TS, Atenafu EG, Forrest D, Savoie L, Bence-Bruckler I, Keating MM, Busque L, Delage R, Xenocostas A, Liew E, Paulson K, Stockley T, Laneuville P, Lipton JH, Kamel-Reid S, Leber B. Kim DDH, et al. Among authors: kim ts. Br J Haematol. 2021 May;193(4):779-791. doi: 10.1111/bjh.17447. Epub 2021 Apr 20. Br J Haematol. 2021. PMID: 33876423 Clinical Trial.
Comparison of the Prognostic Ability of the HCT-CI, the Modified EBMT, and the EBMT-ADT Pre-transplant Risk Scores for Acute Leukemia.
Al-Shaibani E, Cyriac S, Chen S, Lipton JH, Kim DD, Viswabandya A, Kumar R, Lam W, Law A, Al-Shaibani Z, Gerbitz A, Pasic I, Mattsson J, Michelis FV. Al-Shaibani E, et al. Among authors: kim dd. Clin Lymphoma Myeloma Leuk. 2021 Jun;21(6):e559-e568. doi: 10.1016/j.clml.2021.01.022. Epub 2021 Feb 3. Clin Lymphoma Myeloma Leuk. 2021. PMID: 33678592
Benefit of allogeneic transplantation in patients age ≥ 60 years with acute myeloid leukemia is limited to those in first complete remission at time of transplant.
Michelis FV, Messner HA, Atenafu EG, Kim DD, Kuruvilla J, Lipton JH, Uhm J, Loach D, Gupta V. Michelis FV, et al. Among authors: kim dd. Biol Blood Marrow Transplant. 2014 Apr;20(4):474-9. doi: 10.1016/j.bbmt.2013.12.560. Epub 2013 Dec 15. Biol Blood Marrow Transplant. 2014. PMID: 24345422 Free article.
Comparable outcomes post allogeneic hematopoietic cell transplant for patients with de novo or secondary acute myeloid leukemia in first remission.
Michelis FV, Atenafu EG, Gupta V, Kim DD, Kuruvilla J, Lipton JH, Loach D, Seftel MD, Uhm J, Alam N, Lambie A, McGillis L, Messner HA. Michelis FV, et al. Among authors: kim dd. Bone Marrow Transplant. 2015 Jul;50(7):907-13. doi: 10.1038/bmt.2015.59. Epub 2015 Mar 30. Bone Marrow Transplant. 2015. PMID: 25822226
Comparison of Outcomes After Second Allogeneic Hematopoietic Cell Transplantation Versus Donor Lymphocyte Infusion in Allogeneic Hematopoietic Cell Transplant Patients.
Al-Shaibani E, Bautista R, Lipton JH, Kim DD, Viswabandya A, Kumar R, Lam W, Law AD, Al-Shaibani Z, Gerbitz A, Pasic I, Mattsson J, Michelis FV. Al-Shaibani E, et al. Among authors: kim dd. Clin Lymphoma Myeloma Leuk. 2022 May;22(5):e327-e334. doi: 10.1016/j.clml.2021.11.004. Epub 2021 Nov 11. Clin Lymphoma Myeloma Leuk. 2022. PMID: 34866020
53,121 results
You have reached the last available page of results. Please see the User Guide for more information.